Zeiss Wins EU Nod for Cirrus PathFinder AI-Guided OCT Image Assessment

ZEISS Medical Technology has received CE mark approval for Cirrus PathFinder, a clinical support tool with artificial intelligence (AI) integrated for OCT interpretation assistance.

Cirrus PathFinder leverages proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans. It also provides AI-enhanced OCTA image quality and multi-layer segmentation.

It captures images at high speed with HD imaging detail, a wide field of view, and AI decision support.

“At ZEISS, we continue to develop digital diagnostic tools that help streamline workflows, lower costs, improve outcomes, and elevate the patient experience,” said Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. “The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience.”

The system’s AI decision support algorithm interprets data in the clinician’s current workflow, allowing evaluation of hundreds of scans at once in real time. During image acquisition, the AI-guided workflow tool flags areas that may need more detailed imaging.

New operating software offers AI-enhanced visualization of the vascular structure and B-scan averaging of the OCTA structural scans. Increased layer segmentation further boosts diagnostic capability, as well.

New cybersecurity features were designed to meet evolving compliance and security needs. Further, the platform can seamlessly review legacy OCT data combined with other diagnostic modalities.

“ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care,” said Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. “Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into ZEISS CIRRUS PathFinder.”

Earlier this year, the company earned FDA clearance for Intrabeam 700, a platform that provides robotic assistance to support intraoperative radiation therapy (IORT). Intrabeam 700 touts a digital-first architecture that aims to add value for neurooncology and breast cancer therapy.